• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[关于中药上市后风险评估与风险管理的思考]

[Thinking on risk assessment and risk management of post-marketing Chinese medicine].

作者信息

Yu Xueqing, Xie Yanming, Wang Yongyan

机构信息

Institute of Clinical Basic Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.

出版信息

Zhongguo Zhong Yao Za Zhi. 2012 Jan;37(2):262-4.

PMID:22737865
Abstract

Drug risk assessment and management is an important measure for reducing the adverse drug reaction and enhancing medication safety of the patient. Based on the concepts of drug risk assessment and risk management, and domestic and international drug risk management situation, this paper discusses the risk management of post-marketing Chinese medicine.

摘要

药品风险评估与管理是减少药品不良反应、提高患者用药安全性的重要举措。基于药品风险评估与风险管理的概念以及国内外药品风险管理状况，本文探讨了中药上市后的风险管理。

相似文献

1
[Thinking on risk assessment and risk management of post-marketing Chinese medicine].[关于中药上市后风险评估与风险管理的思考]
Zhongguo Zhong Yao Za Zhi. 2012 Jan;37(2):262-4.
2
[Study on method on post-marketing traditonal Chinese medicine safety assessment].[中药上市后安全性评价方法研究]
Zhongguo Zhong Yao Za Zhi. 2011 Oct;36(20):2771-5.
3
[Explore method about post-marketing safety re-evaluation of Chinese patent medicines based on HIS database in real world].基于医院信息系统（HIS）数据库的中成药上市后安全性再评价的真实世界探索方法
Zhongguo Zhong Yao Za Zhi. 2011 Oct;36(20):2779-82.
4
[Sample size calculation in clinical post-marketing evaluation of traditional Chinese medicine].[中药上市后临床评价中的样本量计算]
Zhongguo Zhong Yao Za Zhi. 2011 Oct;36(20):2904-6.
5
[Guidance of FDA risk evaluation and mitigation strategy and enlightenment to drug risk management of post-marketing Chinese medicine].[美国食品药品监督管理局风险评估与缓解策略指南及其对我国上市后中药风险管理的启示]
Zhongguo Zhong Yao Za Zhi. 2011 Oct;36(20):2825-7.
6
[Thought on several problems of post-marketing herbs clinical evaluation in special populations].[关于特殊人群上市后中药临床评价若干问题的思考]
Zhongguo Zhong Yao Za Zhi. 2011 Oct;36(20):2776-8.
7
Challenges in collecting, accessing and evaluating post market surveillance AERS in patients receiving dietary supplements.收集、获取和评估接受膳食补充剂患者的上市后监测不良事件报告系统（AERS）数据时面临的挑战。
Thromb Res. 2005;117(1-2):137-44; discussion 145-51. doi: 10.1016/j.thromres.2005.07.005. Epub 2005 Sep 1.
8
[Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance].[关于如何制定中药上市后监测指南的探索]
Zhongguo Zhong Yao Za Zhi. 2013 Sep;38(18):2943-8.
9
[Study on building index system of risk assessment of post-marketing Chinese patent medicine based on AHP-fuzzy neural network].基于层次分析法-模糊神经网络的中成药上市后风险评估指标体系构建研究
Zhongguo Zhong Yao Za Zhi. 2011 Oct;36(20):2828-30.
10
[Clinical orientation and thought on several problems in post-marketed reassessment of traditional Chinese medicine].[关于中药上市后再评价若干问题的临床定位与思考]
Zhongguo Zhong Yao Za Zhi. 2011 Oct;36(20):2893-7.